Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. / Ørnbjerg, L M; Østergaard, M; Jensen, T; Hørslev-Petersen, K; Stengaard-Pedersen, K; Junker, P; Ellingsen, T; Ahlquist, P; Lindegaard, H; Linauskas, A; Schlemmer, A; Dam, M Y; Hansen, I; Lottenburger, T; Ammitzbøll, C G; Jørgensen, A; Krintel, S B; Raun, J; Hetland, M L; OPERA Study Group ; Lorenzen, Tove (Medlem af forfattersamarbejde).

I: Clinical Rheumatology, Bind 36, Nr. 4, 04.2017, s. 781-789.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Ørnbjerg, LM, Østergaard, M, Jensen, T, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Lottenburger, T, Ammitzbøll, CG, Jørgensen, A, Krintel, SB, Raun, J, Hetland, ML, OPERA Study Group & Lorenzen, T 2017, 'Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial', Clinical Rheumatology, bind 36, nr. 4, s. 781-789. https://doi.org/10.1007/s10067-016-3489-1

APA

Ørnbjerg, L. M., Østergaard, M., Jensen, T., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Hetland, M. L., ... Lorenzen, T. (2017). Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology, 36(4), 781-789. https://doi.org/10.1007/s10067-016-3489-1

CBE

Ørnbjerg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Hetland ML, OPERA Study Group, Lorenzen T. 2017. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology. 36(4):781-789. https://doi.org/10.1007/s10067-016-3489-1

MLA

Vancouver

Author

Ørnbjerg, L M ; Østergaard, M ; Jensen, T ; Hørslev-Petersen, K ; Stengaard-Pedersen, K ; Junker, P ; Ellingsen, T ; Ahlquist, P ; Lindegaard, H ; Linauskas, A ; Schlemmer, A ; Dam, M Y ; Hansen, I ; Lottenburger, T ; Ammitzbøll, C G ; Jørgensen, A ; Krintel, S B ; Raun, J ; Hetland, M L ; OPERA Study Group ; Lorenzen, Tove. / Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. I: Clinical Rheumatology. 2017 ; Bind 36, Nr. 4. s. 781-789.

Bibtex

@article{62b01877cbf04d76bb0b1e4b415d4cd5,
title = "Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial",
abstract = "This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/- adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0-6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/-radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) -1.9 (-3.3; -0.26 mg/cm2) in the MTX + placebo group and -1.8 (-3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = -0.086 (95% confidence interval = -0.15; -0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92-1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.",
keywords = "Absorptiometry, Photon, Adalimumab, Adult, Algorithms, Antirheumatic Agents, Arthritis, Rheumatoid, Bone Density, Bone Diseases, Metabolic, Denmark, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Female, Hand Bones, Humans, Linear Models, Male, Methotrexate, Middle Aged, Multivariate Analysis, Severity of Illness Index, Journal Article, Multicenter Study, Randomized Controlled Trial",
author = "{\O}rnbjerg, {L M} and M {\O}stergaard and T Jensen and K H{\o}rslev-Petersen and K Stengaard-Pedersen and P Junker and T Ellingsen and P Ahlquist and H Lindegaard and A Linauskas and A Schlemmer and Dam, {M Y} and I Hansen and T Lottenburger and Ammitzb{\o}ll, {C G} and A J{\o}rgensen and Krintel, {S B} and J Raun and Hetland, {M L} and {OPERA Study Group} and Ole Slot and Nielsen, {Lars Kj{\ae}r} and Henrik Skj{\o}dt and Ole Majgaard and Tove Lorenzen and Horn, {Hans Christian} and Marcin Kowalski and Johansen, {Inger Lauge} and Pedersen, {Peter Mosborg} and Natalia Manilo and Henning Bliddal",
year = "2017",
month = apr,
doi = "10.1007/s10067-016-3489-1",
language = "English",
volume = "36",
pages = "781--789",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer U K",
number = "4",

}

RIS

TY - JOUR

T1 - Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

AU - Ørnbjerg, L M

AU - Østergaard, M

AU - Jensen, T

AU - Hørslev-Petersen, K

AU - Stengaard-Pedersen, K

AU - Junker, P

AU - Ellingsen, T

AU - Ahlquist, P

AU - Lindegaard, H

AU - Linauskas, A

AU - Schlemmer, A

AU - Dam, M Y

AU - Hansen, I

AU - Lottenburger, T

AU - Ammitzbøll, C G

AU - Jørgensen, A

AU - Krintel, S B

AU - Raun, J

AU - Hetland, M L

AU - OPERA Study Group

AU - Slot, Ole

AU - Nielsen, Lars Kjær

AU - Skjødt, Henrik

AU - Majgaard, Ole

AU - Lorenzen, Tove

AU - Horn, Hans Christian

AU - Kowalski, Marcin

AU - Johansen, Inger Lauge

AU - Pedersen, Peter Mosborg

AU - Manilo, Natalia

AU - Bliddal, Henning

PY - 2017/4

Y1 - 2017/4

N2 - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/- adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0-6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/-radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) -1.9 (-3.3; -0.26 mg/cm2) in the MTX + placebo group and -1.8 (-3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = -0.086 (95% confidence interval = -0.15; -0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92-1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.

AB - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/- adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0-6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/-radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) -1.9 (-3.3; -0.26 mg/cm2) in the MTX + placebo group and -1.8 (-3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = -0.086 (95% confidence interval = -0.15; -0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92-1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.

KW - Absorptiometry, Photon

KW - Adalimumab

KW - Adult

KW - Algorithms

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Bone Density

KW - Bone Diseases, Metabolic

KW - Denmark

KW - Disease Progression

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Female

KW - Hand Bones

KW - Humans

KW - Linear Models

KW - Male

KW - Methotrexate

KW - Middle Aged

KW - Multivariate Analysis

KW - Severity of Illness Index

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

U2 - 10.1007/s10067-016-3489-1

DO - 10.1007/s10067-016-3489-1

M3 - Journal article

C2 - 27921185

VL - 36

SP - 781

EP - 789

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 4

ER -